Evaluation of Anti-Tumour Efficacy of Liposomes Loaded with Rubitecan as Potential Antitumor Drug Delivery System

The present research objective was to characterize the prepared liposomes for in vitro
cytotoxicity assay, cellular uptake studies of liposomes, competitive binding assay and hemolytic
test. Materials and Methods: The prepared liposomes were assessed for the cellular cytotoxicity
of Rubitecan-loaded liposomes on cancer cell linings. Results: The images infer that the uptake
of liposomes had a significant time-dependent fusion method for cellular internalizationquantitative analysis of cellular uptake determined by flow cytometry. The fluorescence intensity
profile is correlated with the results obtained in laser scanning confocal microscopic study. The
results inferred that the conjugated transferrin liposomes entered the cells by surface adherence
were facilitated by endocytosis mediated by the transferrin receptor. The hemolysis value of Tf-Lip/
Rubitecan was less than 2%, which indicated that it had great haemo-compatibility and could be
safe for intravenous injection. Conclusion: This work effectively created and optimized a novel
transferrin liposome conjugated anti-tumor targeted drug delivery system using Rubitecan as
an anticancer agent. The study's findings suggest that transferrin-targeted liposomes enhanced
the delivery of Rubitecan to the tumor, potentially enhancing the drug's anticancer efficacy in
clinical settings.